[EN] NAPHTHYRIDONE COMPOUNDS FOR INHIBITION OF RAF KINASES AND/OR BCR-ABL TYROSINE KINASES<br/>[FR] COMPOSÉS NAPHTYRIDONE POUR L'INHIBITION DE KINASES RAF ET/OU DE TYROSINE KINASES BCR-ABL
申请人:ENLIVEN THERAPEUTICS INC
公开号:WO2022236319A1
公开(公告)日:2022-11-10
The present disclosure relates to compounds and compositions for inhibition of RAF serine/threonine protein kinases and inhibition of Bcr-Abl tyrosine kinases, methods of preparing said compounds and compositions, and their use in the treatment of various cancers, such as melanoma, non-small cell lung cancer, and chronic myeloid leukemia (CML).
本公开涉及抑制RAF丝氨酸/苏氨酸蛋白激酶和Bcr-Abl酪氨酸激酶的化合物和组合物,制备该化合物和组合物的方法,以及它们在治疗各种癌症,如黑色素瘤、非小细胞肺癌和慢性髓细胞白血病(CML)中的用途。